Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Dr. Reddy's Laboratories Ltd ADR
(NY:
RDY
)
14.20
+0.21 (+1.52%)
Streaming Delayed Price
Updated: 3:16 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Dr. Reddy's Laboratories Ltd ADR
< Previous
1
2
3
4
5
6
Next >
Dr. Reddy's Lab Delivers 'Another Good Quarter,' CEO Says As Revenue Jumps 17%
November 05, 2024
Dr. Reddy's Q2 2025 report shows a revenue boost to $957 million, fueled by global generics. North American sales rose 17% year-over-year.
Via
Benzinga
Dr. Reddy’s Q2 & H1FY25 Financial Results
November 05, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year
October 25, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr. Reddy’s Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month
October 14, 2024
From
Dr. Reddy’s Laboratories Inc.
Via
Business Wire
Market Alert: Dr. Reddy’s Labs Reports New Data for Aurigene CAR-T Phase 1, Gets Approvals for Phase 2 Trials Progression
October 09, 2024
Via
AB Newswire
Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India’s First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma
October 08, 2024
From
Aurigene Oncology Limited
Via
Business Wire
Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries
October 02, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr. Reddy's Laboratories – Elliott Wave Technical Analysis
September 20, 2024
Dr Reddy's Laboratories is progressing lower within a counter trend zigzag to terminate Minor Wave 4 Grey around 5600 levels.
Via
Talk Markets
Dr. Reddy's Stock Hit All-Time High Last Month. Ready To Climb Again?
September 03, 2024
Dr. Reddy's Labs sees its Relative Strength Rating enter the 80-plus level.
Via
Investor's Business Daily
Organon Stock Sees Relative Strength Rating Rise To 91
August 27, 2024
On Tuesday, Organon[ stock hit an key technical milestone, seeing its Relative Strength Rating jump to 91, up from 88 the day before.
Via
Investor's Business Daily
Week In Review: Multitude Out-Licenses Tissue Factor ADC To Adcendo In $1 Billion Deal
August 24, 2024
Shanghai Multitude Therapeutics out-licensed global rights for its Tissue Factor ADC to Adcendo in a $1 billion agreement. The value of the agreement includes upfront and milestone payments, with...
Via
Talk Markets
Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold
August 20, 2024
On Tuesday, generic drug maker Organon stock had its Relative Strength (RS) Rating upgraded to 83, up from 78 a day earlier.
Via
Investor's Business Daily
Dr. Reddy’s Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug
August 20, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr. Reddy’s Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar
July 29, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr. Reddy’s Q1FY25 Financial Results
July 27, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
July 10, 2024
Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024
Via
MarketBeat
Should Quality-Oriented Investors Explore DR. REDDY'S LABORATORIES-ADR (NYSE:RDY)?
July 01, 2024
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) can be considered a quality stock. Here's why.
Via
Chartmill
Dr. Reddy's Labs Stock Sees Improved Technical Strength
June 28, 2024
On Friday, Dr. Reddy's Labs ADR stock earned an upgrade to its Relative Strength (RS) Rating, from 66 to 76.
Via
Investor's Business Daily
Haleon To Offload Non-Core Nicotine Therapy Business To Dr. Reddy's For Over $600M
June 26, 2024
Haleon has agreed to sell its nicotine replacement therapy business outside the U.S. to Dr. Reddy's Laboratories SA for £500 million ($632 million). This strategic move allows Haleon to focus on growth...
Via
Benzinga
Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities
June 03, 2024
From
Aurigene Pharmaceutical Services Ltd.
Via
Business Wire
Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business
June 26, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
India Stocks Rally On Modi Election Wave. This Indian Bank Stock Hits High.
June 03, 2024
Exit polls forecast a landslide win and third consecutive term for Prime Minister Narendra Modi in India's general elections.
Via
Investor's Business Daily
Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America
May 28, 2024
From
Dr. Reddy's Laboratories Ltd.
Via
Business Wire
Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
May 21, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
May 21, 2024
From
Alvotech
Via
GlobeNewswire
RDY Stock Earnings: Dr Reddy’s Laboratories Beats EPS, Misses Revenue for Q4 2024
May 07, 2024
RDY stock results show that Dr Reddy's Laboratories beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2024.
Via
InvestorPlace
Dr. Reddy’s Q4 & Full Year FY24 Financial Results
May 07, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
May 03, 2024
From
Dr. Reddy's Laboratories Ltd.
Via
Business Wire
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
March 19, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Global Access to Weight-Loss Treatments: Indian Pharma Giants Eye Affordable Wegovy Alternatives Amid Rising Demand
February 22, 2024
Indian pharmaceutical giants, including Sun Pharma and Cipla, seize the opportunity to develop affordable versions of Novo Nordisk's Wegovy weight-loss treatment. With patents set to expire by...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.